Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.